What Enicil Treats: Main Uses and Benefits

Enicil (Latanoprost) is an ophthalmic medication used for the management of elevated intraocular pressure (IOP). The use of this medicine is relevant for managing high eye pressure, which may assist with maintaining functional stability. Latanoprost is commonly used to help manage chronic conditions, primarily primary open-angle glaucoma and ocular hypertension.

---

Managing Risk and Supporting Functional Stability

Enicil is generally applied in clinical settings for the long-term management of elevated pressure, and is relevant for adults and selected pediatric patients. By helping to reduce the elevated IOP, the medication may assist with managing the potential for visual field loss. This action generally supports the patient in maintaining functional stability and contributes to easing the overall symptom load over the course of the chronic condition.

“The primary benefit is to provide support that helps ease the overall symptom burden associated with the pressure.”

---

Quick Facts

Quick Fact: Relief for Elevated IOP
Therapeutic Role	Generally used to help with the sustained management of high eye pressure (IOP), which is a key risk factor for vision loss.
Condition Categories	Relevant in conditions characterized by periods of heightened pressure, such as glaucoma and ocular hypertension.
Patient Benefit	Contributes to improved comfort and assists with maintaining functional stability by easing the overall symptom burden.

Regulatory References

1. NIH MedlinePlus overview

Eligibility Map: Who Can and Cannot Use Enicil

Eligibility Scope

Use of Enicil is generally allowed for the adult and older adult population. According to European regulatory documents, the medicine may also be used in pediatric patients, though safety data is very limited for infants under one year old. Separately, the US FDA label states that safety and effectiveness have not been established in the general pediatric population.

Populations for Whom Use is Contraindicated

Enicil is contraindicated for any patient with a known hypersensitivity to the active ingredient latanoprost or to any component of the formulation, including the preservative benzalkonium chloride.

Pregnancy and Lactation Eligibility Status

The medicine is not recommended for use in women who are pregnant or breastfeeding, as its metabolites may pass into breast milk.

Eligibility-Related Restrictions

Use requires caution in patients with a history of intraocular inflammation (iritis/uveitis) and should be avoided in cases of active herpes simplex keratitis. Special caution is also specified for aphakic patients or those with a torn posterior lens capsule due to risk factors. The official label does not document specific restrictions for hepatic or renal impairment.

️ Interactions with Other Medicines and Products

The official interaction profile for Enicil (Latanoprost) is highly specific to ophthalmic use, with constraints rigorously documented in government regulatory sources.

Interaction Category	Regulatory Description
Pharmacodynamic Conflict	Co-administration with other ophthalmic prostaglandin analogs (such as bimatoprost or travoprost) is not recommended. This combination is documented to cause a paradoxical elevation in intraocular pressure (IOP).
Chemical Incompatibility	Products containing Thimerosal (or thiomersal) must be administered at least five (5) minutes apart from Enicil. This separation is a mandatory requirement stemming from chemical precipitation observed in vitro.
Timing Requirement	Any other topical ophthalmic drug product must be administered at least five (5) minutes apart from Enicil. This rule ensures proper drug retention and local exposure.
Systemic Interactions	No definitive systemic drug interaction studies have been formally conducted. Regulatory agencies therefore state that no clinically relevant interactions are expected or established with systemically administered medicines, food, alcohol, or herbal products due to the product's localized administration and rapid metabolism.

The regulatory documentation defines the interaction structure primarily through mandatory topical application rules. This includes the functional restriction against other prostaglandin analogs and the specific timing rule for all other eye drops to maintain efficacy and chemical compatibility. Official labels also note that specific data is limited regarding interaction changes in patients with impaired renal or hepatic function.

Molecular Activation and FP Receptor Agonism

This domain describes the primary molecular event: the Latanoprost Acid metabolite selectively and fully activates the Prostaglandin F receptor (FP receptor) located on the ciliary muscle bundles. This specific binding initiates the entire pharmacodynamic cascade, which serves to enhance the eye's fluid clearance capacity.

---

Modulation of the Uveoscleral Outflow Pathway

The activation of the FP receptor leads to structural and physiological changes within the ciliary muscle and the surrounding Extracellular Matrix (ECM). This action directly increases the permeability and conductivity of the uveoscleral pathway, which is the eye's non-conventional fluid drainage route. This mechanism increases the rate of aqueous humor evacuation from the anterior chamber.

---

⏱️ Mechanistic Consequence: Sustained Outflow Adjustment

The enhancement of uveoscleral outflow reduces the resistance to fluid movement, resulting in the reduction of intraocular pressure (IOP). The mechanism is independent of the body's fluid production rate, focusing exclusively on outflow enhancement. The maximal reduction in outflow resistance is observed over several hours as tissue remodeling and fluid dynamics reach a steady state following receptor activation.

How to Use Enicil: Official Administration Guidelines

Enicil (Latanoprost ophthalmic solution) is used according to specific administration, frequency, and handling requirements. The medicine is consistently administered via the topical ophthalmic route as a 0.005% solution, which is applied directly to the surface of the eye.

---

Administration Scope

Feature	Guideline
Route of Administration	Topical ophthalmic route.
Standard Dosing Schedule	One drop in the affected eye(s) once daily.
Maximum Frequency	The dose must not exceed once daily, as more frequent use is strictly prohibited and may reduce the intended IOP-lowering effect.
Optimal Timing	Administration is generally recommended to occur in the evening hours.
Age-Group Rules	The standard one-drop, once-daily dose applies to adults, including the elderly, and is the recommended dosage for pediatric patients where appropriate.

---

Procedural Instructions and Constraints

The official instructions detail specific procedures for proper use. If a dose is missed, treatment must continue with the next scheduled dose; patients should not use an extra dose to compensate. When using other topical eye products, they must be administered at least five (5) minutes apart from Enicil. Furthermore, soft contact lenses must be removed prior to administration and can be reinserted 15 minutes later.

These instructions establish a precise, non-systemic administration pattern and define the necessary conditions, such as the required time intervals between drops, for the proper, label-based methodology for using the medicine.

Research evidence / Overview of Studies for Enicil

Evidence for Use in Primary Open-Angle Glaucoma and Ocular Hypertension

Clinical research and systematic reviews examining this compound largely utilize Randomized Controlled Trials (RCTs). These studies primarily included adult populations with elevated intraocular pressure (IOP). The research focused on monitoring the measured change in eye pressure (IOP) from baseline.

The findings from these trials describe patterns observed in the studies where consistent measurements of change in IOP were reported across the observed patient populations. Reported IOP measurements were often compared to other study treatments, such as timolol, in the research setting. Evidence from subsequent systematic reviews suggests a consistency in the short-term IOP change that was measured in these analyzed RCTs.

Research on Normal-Tension Glaucoma

Enicil was studied for its application in patients diagnosed with Normal-Tension Glaucoma (NTG), a condition where symptoms may vary in intensity. The studies conducted in this population were a mix of RCTs and long-term prospective cohort studies. Researchers primarily examined the change in IOP and outcomes reflecting daily functioning or activity level, such as the rate of visual field progression over time. However, findings were mixed regarding achieving high consistency in the target IOP change across all enrolled NTG patients.

Research Gaps and Remaining Uncertainties

A key research limitation is the focus on the IOP change biomarker in many of the initial trials. While this is a critical outcome, more research focusing on outcomes reflecting daily functioning or activity level over extended periods would help further characterize the effects. Data for certain groups remain insufficient, and the available evidence highlights what is known—the short-term measurements of IOP change—and what is still uncertain—the long-term, functional outcomes for all patient types.

Key Studies & References

1. The Effect of Latanoprost on Intraocular Pressure during 12 Months of Treatment for Normal-tension Glaucoma
2. Long-Term Effectiveness and Safety of Tafluprost, Travoprost, and Latanoprost in Korean Patients with Primary Open-Angle Glaucoma or Normal-Tension Glaucoma: A Multicenter Retrospective Cohort Study (LOTUS Study)
3. Latanoprost Ophthalmic Solution: FDA-Approved Indications, Adverse Effects, and Storage

Common questions about Enicil (FAQ)

Q: How quickly does Enicil usually start to work after taking it?

The onset of intraocular pressure (IOP) reduction is typically observed approximately 3 to 4 hours after the eye drop is administered. The full or maximum pressure-lowering effect is generally reached after about 8 to 12 hours.

---

Q: How long can I realistically expect to take Enicil for this condition?

Enicil is indicated for the sustained, long-term management of elevated eye pressure. Clinical data available from studies lasting one to two years have shown a stable pressure-lowering effect with no indication of diminishing effectiveness over that period.

---

Q: Is it normal to feel a bit dizzy when first starting Enicil?

According to official product information, dizziness has been listed as an uncommon side effect. If any unusual reaction, such as dizziness, is experienced, it is recommended to consult a healthcare provider.

---

Q: Can Enicil cause stomach upset, and is that a common side effect?

Official adverse reaction lists primarily focus on effects in or around the eye. Gastrointestinal issues like stomach upset are not listed among the very common, common, or uncommon adverse reactions reported during the main clinical trials.

---

Q: Can Enicil affect sleep patterns, like causing insomnia or drowsiness?

Official information does not list insomnia (trouble sleeping) or drowsiness among the frequently reported side effects. Most reported side effects are localized to the eye itself.

---

Q: What are the most serious, but rare, side effects of Enicil I should watch for?

The official product information lists some rare events, including swelling in the back of the eye known as macular edema and the exacerbation of asthma or the reactivation of a previous herpes simplex keratitis infection.

---

Q: Is Enicil a long-term medication, or is it typically for short periods?

Enicil is officially indicated for conditions that require the sustained reduction of eye pressure. These conditions are typically managed with long-term, ongoing treatment.

---

Q: Can older adults use Enicil safely without major concerns?

Official labeling states that no overall differences in the effectiveness or safety of the medicine have been observed between older adults (geriatric) and younger adult patients. No specific dose adjustment is typically needed for the elderly population.

---

Q: Is it safe to take Enicil if I already have high blood pressure?

Due to the localized ophthalmic administration and rapid systemic clearance, regulatory documents state no clinically relevant interactions are established or expected with systemically administered medicines, including those for high blood pressure.

---

Q: What happens if I accidentally take two doses of Enicil close together?

The official guidance emphasizes that the dose should not exceed once daily, as more frequent administration may reduce the expected pressure-lowering effect or cause pressure elevation.

---

Q: Is Enicil safe for people with liver or kidney issues?

Regulatory documents state that no formal studies have been conducted to determine the safety or requirement for dose adjustment in patients with hepatic (liver) or renal (kidney) impairment. As a result, specific data on this patient population are not available.

---

Q: Do other medicines, like vitamins or supplements, interact with Enicil?

Since Enicil is administered only to the eye and is quickly eliminated from the bloodstream, no systemic drug interactions are expected or established with systemically administered products, including vitamins or herbal supplements.

---

Q: What is the main benefit or advantage of using Enicil over alternatives?

Official clinical trial data indicates that Latanoprost reduces eye pressure (IOP) by a range of 22% to 39% over time. The observed IOP reduction has been shown in comparative studies to be equivalent to or comparable with the effect achieved by Timolol 0.5% twice daily.

---

Q: Do children ever get prescribed Enicil, and for what?

Enicil may be used in pediatric patients for conditions such as pediatric glaucoma or elevated eye pressure. However, official safety data is very limited for infants under one year old.

---

Q: What research supports the use of Enicil for [specific indication]?

The strongest body of evidence supporting its use comes from Randomized Controlled Trials (RCTs) conducted in adults. These trials consistently demonstrated a significant reduction of intraocular pressure (IOP) for patients with Primary Open-Angle Glaucoma and Ocular Hypertension.

---

Q: Can I crush or split the Enicil tablet if it's hard to swallow?

Enicil is manufactured solely as an ophthalmic solution (eye drops). Since it is not a pill or tablet intended to be taken by mouth, instructions for crushing or splitting do not apply.

---

Q: How long does Enicil stay in your system after you stop taking it?

Once absorbed systemically (into the blood), the active ingredient is rapidly eliminated. Official pharmacokinetic data shows that the active acid has a very short half-life of only about 17 minutes in the plasma.

---

Q: What's the evidence base for Enicil from major medical trials?

The evidence base comes primarily from Randomized Controlled Trials (RCTs) in adults. These studies focus on the objective, measured change in intraocular pressure (IOP) from the population's baseline measurement.

---

Q: Does Enicil impact fertility or hormones?

Based on animal studies, official product information indicates that Latanoprost was found to have no effect on either male or female fertility.

---

Q: Does taking Enicil for a long time reduce its effectiveness?

Clinical trials that monitored patients for up to one to two years reported a stable, consistent pressure-lowering effect throughout the entire treatment period, with no sign of diminishing effectiveness over time.

---

Q: Is there a maximum time someone can safely be on Enicil?

Safety data from open-label studies has been reported for up to five years of use. However, regulatory documents indicate that the full long-term implications, especially regarding permanent iris pigmentation, are not fully characterized beyond the five-year study period.

---

Q: Is Enicil used for acute flare-ups or for maintenance treatment?

The official indication is for the reduction of elevated eye pressure in conditions that require sustained, ongoing maintenance of fluid dynamics. It is not intended for acute, short-term relief or flare-ups.

Unopened bottles of Enicil (Latanoprost ophthalmic solution) must be refrigerated at 2 C to 8 C (36 F to 46 F) and must not be frozen. The product must be kept in its original outer carton to protect it from light. The cap must be kept tightly closed when not in use.

Storage State	Temperature Range	Discard Date
Unopened Bottle	2 C to 8 C	According to package expiration
Opened Bottle (In-Use)	Up to 25 C (77 F)	6 weeks (42 days) after opening

All medication must be stored out of the sight and reach of children and pets. Unused or expired medication should not be flushed down a toilet or poured down a drain unless specifically instructed. Dispose of the unused product in accordance with local regulations.